Skip to content
10-Q

Quarterly Report

Dermata Therapeutics, Inc. DRMA DRMAW

0001493152-26-022719

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 4.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 3.86M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 515.47K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.48M
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$7.8M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $6.95M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.52M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.41M
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.22M
Stockholders Equity Q1 2026 · Mar 31, 2025 $7.3M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.56M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.05M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.64M
Total Assets Q1 2026 · Mar 31, 2026 $7.47M
Total Assets Q1 2026 · Dec 31, 2025 $7.86M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.48
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$4.47
Eps Basic Q1 2026 · Mar 31, 2026 −$0.48
Eps Basic restated Q1 2026 · Mar 31, 2025 −$4.47
Sga Expense Q1 2026 · Mar 31, 2026 $1.54M
Sga Expense Q1 2026 · Mar 31, 2025 $1.06M
Rd Expense Q1 2026 · Mar 31, 2026 $383.72K
Rd Expense Q1 2026 · Mar 31, 2025 $1.28M
Net Income Q1 2026 · Mar 31, 2026 −$1.85M
Net Income Q1 2026 · Mar 31, 2025 −$2.3M
Operating Income Q1 2026 · Mar 31, 2026 −$1.93M
Operating Income Q1 2026 · Mar 31, 2025 −$2.34M